186 related articles for article (PubMed ID: 36461603)
1. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
Yuan J; Liu Z; Wu Z; Yang J; Yang J
Int Immunopharmacol; 2022 Dec; 113(Pt A):109411. PubMed ID: 36461603
[TBL] [Abstract][Full Text] [Related]
2. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
3. Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.
Jiang C; Liu Z; Yuan J; Wu Z; Kong L; Yang J; Lv T
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901767
[TBL] [Abstract][Full Text] [Related]
4. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
5. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
6. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
[TBL] [Abstract][Full Text] [Related]
7. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
8. Guanylate-binding proteins signature predicts favorable prognosis, immune-hot microenvironment, and immunotherapy response in hepatocellular carcinoma.
Ning Y; Fang S; Fang J; Lin K; Nie H; Xiong P; Qiu P; Zhao Q; Wang H; Wang F
Cancer Med; 2023 Aug; 12(16):17504-17521. PubMed ID: 37551111
[TBL] [Abstract][Full Text] [Related]
9. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.
Qu J; Sun F; Hou Y; Qi H; Sun X; Xing L
BMC Cancer; 2023 Jun; 23(1):549. PubMed ID: 37322434
[TBL] [Abstract][Full Text] [Related]
10. A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Yang Y; Xiao W; Liu R; Gao L; Chen J; Kan H
J Immunol Res; 2022; 2022():4983532. PubMed ID: 36405011
[TBL] [Abstract][Full Text] [Related]
11. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
12. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
Front Immunol; 2022; 13():856186. PubMed ID: 35479067
[TBL] [Abstract][Full Text] [Related]
13. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
14. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
17. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.
Li W; Wu R; Zhang S; Zhao Y; Li L; Hu Z; Su Q; Mang Y; Zhang X; Dong Y; Zheng K; Ran J; Li L
Clin Transl Oncol; 2023 Jul; 25(7):2099-2115. PubMed ID: 36708372
[TBL] [Abstract][Full Text] [Related]
18. Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
Peng X; Shi Y; Zhang B; Xu C; Lang J
J Med Virol; 2023 Sep; 95(9):e29084. PubMed ID: 37721443
[TBL] [Abstract][Full Text] [Related]
19. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Yang L; Zhang W; Yan Y
Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
